110 related articles for article (PubMed ID: 14531831)
1. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
Lhotta K
Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
[No Abstract] [Full Text] [Related]
2. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Fujimori S; Ooyama K; Ooyama H; Moromizato H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
[TBL] [Abstract][Full Text] [Related]
3. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
George J
Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
5. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
6. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
7. Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Gao H
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1869-1871. PubMed ID: 31680085
[TBL] [Abstract][Full Text] [Related]
8. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.
Ye X; Wu J; Tang K; Li W; Xiong C; Zhuo L
Medicine (Baltimore); 2019 Apr; 98(15):e15214. PubMed ID: 30985721
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism in biological transport in the kidney: Urate transporter URAT1].
Hosoyamada M; Shibasaki T; Ichida K
Nihon Rinsho; 2006 Feb; 64 Suppl 2():176-9. PubMed ID: 16523883
[No Abstract] [Full Text] [Related]
10. [Anti hyperuricemic agents].
Ogino K; Hisatome I; Shigemasa C
Nihon Rinsho; 2003 Jan; 61 Suppl 1():197-201. PubMed ID: 12629717
[No Abstract] [Full Text] [Related]
11. [Impact of serum uric acid level on the cardiovascular system as a risk factor].
Hisatome I
Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):325-9. PubMed ID: 21139282
[No Abstract] [Full Text] [Related]
12. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?
Jansen TL; Reinders MK; van Roon EN; Brouwers JR
Clin Exp Rheumatol; 2004; 22(5):651. PubMed ID: 15485024
[No Abstract] [Full Text] [Related]
13. Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?
Gravatt L
N Z Med J; 2013 Sep; 126(1382):118-9. PubMed ID: 24154779
[No Abstract] [Full Text] [Related]
14. [Essential hypertension].
Murakami H; Shimamoto K
Nihon Rinsho; 2003 Jan; 61 Suppl 1():235-40. PubMed ID: 12629724
[No Abstract] [Full Text] [Related]
15. [Isolated or combined drug therapy of hyperuricemia?].
Mertz DP
Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
[No Abstract] [Full Text] [Related]
16. Benzbromarone: availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt onbenzbromarone).
Day R; Lee H; Graham G; Williams K
N Z Med J; 2013 Sep; 126(1382):124-6. PubMed ID: 24154781
[No Abstract] [Full Text] [Related]
17. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review.
Vinik O; Wechalekar MD; Falzon L; Buchbinder R; van der Heijde DM; Bombardier C
J Rheumatol Suppl; 2014 Sep; 92():70-4. PubMed ID: 25180131
[TBL] [Abstract][Full Text] [Related]
18. [Management of hyperuricemia in diabetes].
Hirai A; Saito Y
Nihon Rinsho; 1997 Nov; 55 Suppl():781-5. PubMed ID: 9434564
[No Abstract] [Full Text] [Related]
19. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
20. [Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
Yamanaka H
Nihon Rinsho; 2003 Jan; 61 Suppl 1():202-8. PubMed ID: 12629718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
